Skip to main content
Top

04-05-2024 | Breast Cancer

Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results

Authors: Odilon Assan, Victoria Memoli, Laurence Guillaumie, Véronique Turcotte, Martine Lemay, Anne Dionne, Julie Lemieux, Louise Provencher, Carolyn Gotay, Marijn de Bruin, Line Guénette, Sophie Lauzier

Published in: Journal of Cancer Survivorship

Login to get access

Abstract

Purpose

Adjuvant endocrine therapy (AET) reduces recurrence risk after hormone receptor-positive breast cancer, but non-adherence is common. We pilot-tested SOIE, a program to enhance AET experience and adherence, to assess its acceptability, feasibility, and effects on psychosocial precursors of AET adherence.

Methods

We conducted a 12-month pilot randomized controlled trial among women who had a first AET prescription. Intervention group received SOIE while control group received usual care. Psychosocial factors from the Theory of Planned Behavior (TPB) (intention – primary outcome -, attitude, subjective norm, behavioral control), additional constructs (AET knowledge, social support, coping planning), impact of AET services received, and adherence were measured by questionnaires at baseline, 3-month, and 12-month endpoints. Group patterns were compared using repeated measures analyses with generalized estimating equations.

Results

A total of 106 women were randomized (participation = 54.9%; intervention n = 52; control n = 54; retention = 93.8%). Among SOIE women, ≥ 90% received the program components and were satisfied. Both groups scored high on adherence intentions and group patterns over time were not statistically different. In the intervention group, AET knowledge and coping planning with side effects increased (group-by-time p-value = .002 and .016), a higher proportion reported that AET services received helped them take their AET (p < .05) and have a consistent daily intake (p = .01).

Conclusion

SOIE is feasible and acceptable for survivors with an AET. SOIE did not significantly impact adherence intentions but was beneficial for other program outcomes and daily intake.

Implications for Cancer Survivors

SOIE may represent an encouraging avenue to enhance supportive care and empower survivors with managing AET.
Appendix
Available only for authorised users
Literature
4.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84. https://doi.org/10.1016/s0140-6736(11)60993-8.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84. https://​doi.​org/​10.​1016/​s0140-6736(11)60993-8.CrossRef
10.
go back to reference Lambert-Côté L, Bouhnik A-D, Bendiane M-K, Bérenger C, Mondor M, Huiart L, et al. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases. Breast Cancer Res Treat. 2020;180:777–90.CrossRefPubMed Lambert-Côté L, Bouhnik A-D, Bendiane M-K, Bérenger C, Mondor M, Huiart L, et al. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases. Breast Cancer Res Treat. 2020;180:777–90.CrossRefPubMed
12.
go back to reference Tervonen HE, Daniels B, Tang M, Preen DB, Pearson SA. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients. Pharmacoepidemiol Drug Saf. 2019;28:812–20.CrossRefPubMed Tervonen HE, Daniels B, Tang M, Preen DB, Pearson SA. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients. Pharmacoepidemiol Drug Saf. 2019;28:812–20.CrossRefPubMed
18.
go back to reference Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence. 2017;11:305–22.CrossRefPubMedPubMedCentral Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Prefer Adherence. 2017;11:305–22.CrossRefPubMedPubMedCentral
25.
go back to reference Turcotte V, Guillaumie L, Lemay M, Dionne A, Lemieux J, Provencher L, Lauzier S. The perspective of breast cancer women participating in an adherence-enhancing program for adjuvant endocrine therapy. Abstracts of the 25th Annual Meeting of ESPACOMP, the international society for medication adherence. Int J Clin Pharm. 2022;44:281. https://doi.org/10.1007/s11096-021-01373-5.CrossRef Turcotte V, Guillaumie L, Lemay M, Dionne A, Lemieux J, Provencher L, Lauzier S. The perspective of breast cancer women participating in an adherence-enhancing program for adjuvant endocrine therapy. Abstracts of the 25th Annual Meeting of ESPACOMP, the international society for medication adherence. Int J Clin Pharm. 2022;44:281. https://​doi.​org/​10.​1007/​s11096-021-01373-5.CrossRef
26.
go back to reference Bartholomew L, Parcel G, Kok G, Gottlieb N, Fernandez M. Planning health promotion programs: an intervention mapping approach Jossey-Bass. 3rd ed. ed. Hoboken, N.J., US: Jossey-Bass/Wiley; 2011. Bartholomew L, Parcel G, Kok G, Gottlieb N, Fernandez M. Planning health promotion programs: an intervention mapping approach Jossey-Bass. 3rd ed. ed. Hoboken, N.J., US: Jossey-Bass/Wiley; 2011.
28.
go back to reference Fishbein M, Ajzen I. Predicting and changing behavior: the reasoned action approach. New York, US: Taylor & Francis; 2011.CrossRef Fishbein M, Ajzen I. Predicting and changing behavior: the reasoned action approach. New York, US: Taylor & Francis; 2011.CrossRef
29.
go back to reference Humphries B, Collins S, Guillaumie L, Lemieux J, Dionne A, Provencher L, et al. Women’s beliefs on early adherence to adjuvant endocrine therapy for breast cancer: a theory-based qualitative study to guide the development of community pharmacist interventions. Pharmacy (Basel, Switzerland). 2018;6:53. https://doi.org/10.3390/pharmacy6020053.CrossRefPubMed Humphries B, Collins S, Guillaumie L, Lemieux J, Dionne A, Provencher L, et al. Women’s beliefs on early adherence to adjuvant endocrine therapy for breast cancer: a theory-based qualitative study to guide the development of community pharmacist interventions. Pharmacy (Basel, Switzerland). 2018;6:53. https://​doi.​org/​10.​3390/​pharmacy6020053.CrossRefPubMed
32.
go back to reference La Gagné C. mesure des variables théoriques et des comportements. In: Godin G, editor. Les comportements dans le domaine de la santé: Comprendre pour mieux intervenir. Montréal, CA: Les Presses de l’Université de Montréal; 2012. p. 231–92. La Gagné C. mesure des variables théoriques et des comportements. In: Godin G, editor. Les comportements dans le domaine de la santé: Comprendre pour mieux intervenir. Montréal, CA: Les Presses de l’Université de Montréal; 2012. p. 231–92.
33.
go back to reference Grégoire J, Moisan J. Assessment of adherence to drug treatment in database research. In: Elseviers Mea, editor. Drug utilization research: methods and applications. First ed: Wiley & Sons, Ltd.; 2016;369–80. Grégoire J, Moisan J. Assessment of adherence to drug treatment in database research. In: Elseviers Mea, editor. Drug utilization research: methods and applications. First ed: Wiley & Sons, Ltd.; 2016;369–80.
35.
39.
go back to reference Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, et al. The Patient’s Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. 2013;24:1505–12. https://doi.org/10.1093/annonc/mds653.CrossRefPubMed Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, et al. The Patient’s Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. 2013;24:1505–12. https://​doi.​org/​10.​1093/​annonc/​mds653.CrossRefPubMed
42.
go back to reference Elseviers M, Vrijens B. Assessment of medication adherence in field research. In: Elseviers M, Wettermark B, Almarsdttir A, editors. Drug utilization research: methods and applications. US: Wiley-Blackwell; 2016. p. 536.CrossRef Elseviers M, Vrijens B. Assessment of medication adherence in field research. In: Elseviers M, Wettermark B, Almarsdttir A, editors. Drug utilization research: methods and applications. US: Wiley-Blackwell; 2016. p. 536.CrossRef
43.
go back to reference Bélanger-Gravel A, Godin G, Vézina-Im L-A. La relation intention-comportement et les stratégies de changement post-intentionnelles. In: Godin G, editor. Les comportements dans le domaine de la santé: Comprendre pour mieux intervenir. Montréal, CA: Les Presses de l’Université de Montréal; 2012. p. 79–106.CrossRef Bélanger-Gravel A, Godin G, Vézina-Im L-A. La relation intention-comportement et les stratégies de changement post-intentionnelles. In: Godin G, editor. Les comportements dans le domaine de la santé: Comprendre pour mieux intervenir. Montréal, CA: Les Presses de l’Université de Montréal; 2012. p. 79–106.CrossRef
52.
go back to reference Weiner BJP, Lewis CCP, Sherr KP. Practical implementation science moving evidence into action. New York: Springer Publishing Company; 2022.CrossRef Weiner BJP, Lewis CCP, Sherr KP. Practical implementation science moving evidence into action. New York: Springer Publishing Company; 2022.CrossRef
Metadata
Title
Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results
Authors
Odilon Assan
Victoria Memoli
Laurence Guillaumie
Véronique Turcotte
Martine Lemay
Anne Dionne
Julie Lemieux
Louise Provencher
Carolyn Gotay
Marijn de Bruin
Line Guénette
Sophie Lauzier
Publication date
04-05-2024
Publisher
Springer US
Published in
Journal of Cancer Survivorship
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-024-01599-y
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare